Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review

Michael A. Vogelbaum, Daria Krivosheya, Hamid Borghei-Razavi, Nader Sanai, Michael Weller, Wolfgang Wick, Riccardo Soffietti, David A. Reardon, Manish K. Aghi, Evanthia Galanis, Patrick Y. Wen, Martin van den Bent, Susan Chang

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics are currently available, and much effort has been expended to identify new drugs capable of slowing tumor progression. The phase 0 trial design was developed to facilitate early identification of promising agents for cancer that should undergo accelerated approval. This design features an early in-human study that enrolls a small number of patients who receive subtherapeutic doses of medication with the goals of describing pharmacokinetics through drug blood level measurements and determining intratumoral concentrations of the investigational compound as well as pharmacodynamics by studying the biochemical and physiological effects of drugs. In neuro-oncology, however, the presence of the blood-brain barrier and difficulty in obtaining brain tumor tissue warrant a separate set of considerations. In this paper, we critically reviewed the protocols used in all brain tumor related in-human phase 0 and phase 0-like ("window of opportunity") studies between 1993 and 2018, as well as ongoing clinical trials, and identified major challenges in trial design as applied to central nervous system tumors that include surgical specimen collection and storage, brain tumor drug level analysis, and confirmation of drug action. We therefore propose that phase 0 trials in neuro-oncology should include (i) only patients in whom a resection of the tumor is planned, (ii) use of clinical doses of an investigational agent, (iii) tissue sampling from enhancing and non-enhancing portions of the tumor, and (iv) assessment of drug-specific target effects. Standardization of clinical protocols for phase 0/window of opportunity studies can help accelerate the development of effective treatments for glioblastoma.

Original languageEnglish (US)
Pages (from-to)1568-1579
Number of pages12
JournalNeuro-oncology
Volume22
Issue number11
DOIs
StatePublished - Nov 26 2020

Keywords

  • clinical trial
  • glioblastoma
  • pharmacodynamics
  • pharmacokinetics
  • phase 0

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review'. Together they form a unique fingerprint.

Cite this